BiotechTube

Teriparatide (FORTEO) + Placebos

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Osteogenesis Imperfecta

Conditions

Osteogenesis Imperfecta

Trial Timeline

Jun 1, 2005 → Jan 1, 2011

NCT ID
NCT00131469

About Teriparatide (FORTEO) + Placebos

Teriparatide (FORTEO) + Placebos is a approved stage product being developed by Eli Lilly for Osteogenesis Imperfecta. The current trial status is completed. This product is registered under clinical trial identifier NCT00131469. Target conditions include Osteogenesis Imperfecta.

What happened to similar drugs?

0 of 6 similar drugs in Osteogenesis Imperfecta were approved

Approved (0) Terminated (2) Active (4)
🔄Zoledronic AcidNovartisPhase 3
🔄Romosozumab + BisphosphonateAmgenPhase 3
❌DenosumabAmgenPhase 3
❌Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
🔄setrusumabUltragenyx PharmaceuticalPhase 3
🔄Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00131469ApprovedCompleted

Competing Products

16 competing products in Osteogenesis Imperfecta

See all competitors
ProductCompanyStageHype Score
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 2
35
Zoledronic AcidNovartisPhase 3
40
Romosozumab + BisphosphonateAmgenPhase 3
47
RomosozumabAmgenPhase 1
29
DenosumabAmgenPhase 3
32
Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
32
FresolimumabSanofiPhase 1
29
SAR439459 + PlaceboSanofiPhase 1
21
BPS804Ultragenyx PharmaceuticalPhase 2
29
SetrusumabUltragenyx PharmaceuticalPhase 2/3
36
SetrusumabUltragenyx PharmaceuticalPhase 2
21
BPS804Ultragenyx PharmaceuticalPhase 2
21
setrusumabUltragenyx PharmaceuticalPhase 3
38
setrusumab + zoledronic acid (optional)Ultragenyx PharmaceuticalPhase 2
29
Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3
38